Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended

2024-511334-12-00 Smoldering Multiple Myeloma 2018-11-19
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 BRAF V600 mutation–positive unresectable or metastatic 2018-10-30
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 high risk diffuse large B-cell lymphoma 2018-08-28
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastat… Ended

2024-511649-21-00 Advanced cancer of the stomach or the gastroesophageal 2018-08-01
A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-… Ended

2024-515755-37-00 Limited disease small-cell lung cancer 2018-07-31
A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy Ended

2024-510713-15-00 Localised and operable soft tissue sarcomas 2018-07-30
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Primary Myelofibrosis (PMF), Post-polycythemia Vera or 2018-07-27
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended

2022-501038-48-00 Diffuse Large B-Cell Lymphoma 2018-07-26
A clinical study to confirm the doses of selexipag to be used in children with pulmonary arterial hypertension Ended

2022-503042-42-00 Pulmonary Arterial Hypertension 2018-07-23
Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocri… Ended

2023-505286-84-00 Pancreatic well differentiated neuroendocrine tumors (N 2018-06-25
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOi… Ended

2024-514058-59-00 Patients with metastatic clear cell renal cell carcinom 2018-06-11
Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on … Ended

2024-513027-16-00 Resectable mucosal melanomas 2018-05-28
Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended

2024-517476-38-00 Marginal Zone Lymphoma 2018-05-14
START : Study on Androgen Receptor and Triple Negative Breast Cancer Ended

2024-516638-36-00 Triple-negative androgen receptor positive (molecular a 2018-03-14
Trial on efficacy and safety of vaccination of newly diagnosed glioblastoma patients with the patient's own immune cells. Ended

2024-514820-18-00 newly diagnosed glioblastoma 2018-03-07
Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse… Ended

2023-510556-22-00 non-Hodgkin lymphoma (NHL) 2018-03-05
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combinatio… Ended

2024-514205-60-00 Triple Negative Breast Cancer 2018-02-15
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended

2024-513070-21-00 Relapsed Acute Lymphoblastic Leukemia (ALL) 2018-02-15
Darolutamide vs ADT in hormone naïve Pca Ended

2024-510840-30-00 Hormone Naive Prostate Cancer 2017-12-01
CRITICS-II Ended

2023-503248-15-00 Patients with TNM 8th ed stage IB-IIC gastric adenocaci 2017-10-09
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended

2023-510159-53-01 peritoneal dissemination in stomach cancer patients 2017-09-28
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984)… Ended

2024-511791-32-00 Multiple Myeloma 2017-08-15
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended

2023-509923-42-00 HER2- positive breast cancer 2017-07-06
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment Ended

2024-510948-31-00 cMET-dependent malignancies 2017-07-04